Breast Cancer

PV QA 4 - Poster Viewing Q&A 4

TU_6_3381 - Patient Reported Outcomes From a Prospective Risk-Adapted Breast IORT Registry Trial

Tuesday, October 23
2:45 PM - 4:15 PM
Location: Innovation Hub, Exhibit Hall 3

Patient Reported Outcomes From a Prospective Risk-Adapted Breast IORT Registry Trial
J. R. Olsen1,2, J. W. Ridings1,2, J. Dickinson3, M. DeWing2, L. Pomerenke2, I. Sharon2, C. Dial4, A. Gascoigne4, J. R. Jones4, L. Olsen2, J. Chilson Foy4, A. Clemons2, S. Durazo2, A. Ulloa5, and J. H. Petit4; 1Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, 2Memorial Hospital, University of Colorado Health, Colorado Springs, CO, 3Northern Colorado Surgical Associates, Poudre Valley Hospital, University of Colorado Health, Fort Collins, CO, 4Department of Radiation Oncology, Poudre Valley Hospital, Fort Collins, CO, 5UCHealth, Poudre Valley Hospital, Fort Collins, CO

Purpose/Objective(s): Intraoperative radiotherapy (IORT) as a component of breast conservation therapy (BCT) is a treatment option for select breast cancer patients as described in the updated 2016 ASTRO consensus criteria. Only limited patient-reported outcomes (PRO) data are available in the current literature following IORT. Herein, we report PRO collected prospectively from a risk-adapted breast IORT registry trial.

Materials/Methods: Seventy-seven patients with early-stage breast cancer meeting the 2009 ASTRO suitable criteria for accelerated partial breast irradiation (APBI) underwent IORT at the time of lumpectomy and sentinel lymph node procedure on a prospective IRB-approved institutional registry trial between 11/2011 and 1/2018. All patients received a single 20 Gy radiotherapy fraction intraoperatively using a 50 kV balloon-based electronic brachytherapy device, which was prescribed to the balloon surface. Patients not meeting the 2009 APBI suitable criteria based on final pathology received whole breast external beam radiotherapy (WBI) following surgery. PRO were measured using a clinical cosmesis form, the EORTC QLQ-C30, and the breast specific EORTC QLQ-BR23 modules at baseline (prior to therapy) and 1, 6, and 12 months following IORT. Differences at each follow-up time were compared to baseline using the Student’s t-test, with Bonferroni correction applied to account for multiple comparisons.

Results: The median (range) age was 69 (60-85) years. Sixty patients received IORT alone, and 17 received WBI following IORT due to presence of adverse pathologic features. PRO at baseline, 1, 6, and 12 months were available for 77, 71, 60, and 42 patients, respectively, given the data available for patients up to 1/2018. Although increased breast pain, swelling, sensitivity, and skin irritation were noted 1 month following IORT (p<0.0001 for all parameters), no significant difference in any parameter compared to baseline was noted at 6 months and 12 months. EORTC QLQ-C30 physical, emotional, and global health parameters were similar at 1, 6, and 12 months following IORT compared to baseline. At 12 months, excellent, good, fair, and poor physician reported cosmesis was noted in 54%, 33%, 10%, and 3% of patients, respectively.

Conclusion: Excellent PRO were observed following IORT as a component of risk-adapted early stage breast cancer therapy on a prospective registry trial. These data represent the largest PRO series reported to date for IORT delivered concurrent with lumpectomy, and may be useful when counseling patients regarding IORT as a component of BCT.

Author Disclosure: J.R. Olsen: Employee; University of Colorado Health. Senior Associate Editor; International Journal of Radiation Oncology Biolog. J. Ridings: None. J. Dickinson: None. M. DeWing: None. C. Dial: None. L. Olsen: Employee; University of Colorado. J. Chilson Foy: Employee, research dept; uchealth - Poudre Valley Hospital. A. Ulloa: Employee, Research Dept; UCHealth - Poudre Valley Hospital. J.H. Petit: Chair of Cancer Committee; Poudre Valley Health System.

Jane Witter Ridings, MD

Presentation(s):

Send Email for Jane Witter Ridings


Assets

TU_6_3381 - Patient Reported Outcomes From a Prospective Risk-Adapted Breast IORT Registry Trial



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Patient Reported Outcomes From a Prospective Risk-Adapted Breast IORT Registry Trial